| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(6 months ago) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 6 months from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 7 months from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 19 days ago) | |
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 6 months from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(1 year, 9 months from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(7 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) | |
Trelegy Ellipta is owned by Glaxosmithkline.
Trelegy Ellipta contains Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate.
Trelegy Ellipta has a total of 15 drug patents out of which 2 drug patents have expired.
Expired drug patents of Trelegy Ellipta are:
- US7776895
- USRE44874
Trelegy Ellipta was authorised for market use on 18 September, 2017.
Trelegy Ellipta is available in powder;inhalation dosage forms.
Trelegy Ellipta can be used as maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol, method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd, indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; maintenance treatment of asthma in patients 18 yrs and older, or chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema, method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application, method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application, indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; and asthma.
The generics of Trelegy Ellipta are possible to be released after 29 November, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Sep 9, 2023 |
| New Strength (NS) | Sep 9, 2023 |
Market Authorisation Date: 18 September, 2017
Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via top...
Dosage: POWDER;INHALATION
TRELEGY ELLIPTA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic